The Winship Cancer Institute of Emory University (Winship) planning and evaluation process, overseen by the Executive Director, Walter J. Curran, Jr., MD, is responsible for the systematic planning and evaluation of Winship, its research programs, shared resources, clinical research enterprise, and clinical operations. Winship relies on the input of expert internal and external consultants and leaders to plan and evaluate its strategic research priorities and for the assessment of the progress of research programs, impact of shared resources, administrative support, and organizational structure. These activities are directed internally by the Winship Internal Advisory Board and the Winship Executive Committee. An External Advisory Board (EAB) is composed of a renowned group of cancer center directors, program leaders, researchers, and administrators from other NCI-designated cancer centers across the country. The EAB is charged to provide critical evaluation of Winship's activities and strategic plan. During the current funding period, input from each of the boards and committees discussed in this section Winship to improve processes and elevate the level of its science. Thorough planning and evaluation has led to the development of the Winship 2016 ? 2018 Strategic Plan. The plan will guide the centers continued develoment during the next funding cycle. The funds requested in addition to committed institutional funds will provide support for these important advisory endeavors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138292-12
Application #
9905354
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
12
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Richardson, Alessandra M; Havel, Lauren S; Koyen, Allyson E et al. (2018) Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion. Clin Cancer Res 24:420-432
Goldstein, Jordan S; Nastoupil, Loretta J; Han, Xuesong et al. (2018) Disparities in survival by insurance status in follicular lymphoma. Blood 132:1159-1166
Guidot, Daniel M; Switchenko, Jeffrey M; Nastoupil, Loretta J et al. (2018) Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk Lymphoma 59:888-895
Jin, Lingtao; Chun, Jaemoo; Pan, Chaoyun et al. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell 34:315-330.e7
Chowdhary, Mudit; Okwan-Duodu, Derick; Switchenko, Jeffrey M et al. (2018) Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. J Neurooncol 136:289-298
Chen, Zhengjia; Zheng, Youyun; Wang, Zhibo et al. (2018) Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs. Contemp Clin Trials Commun 12:145-153
Halani, Sameer H; Yousefi, Safoora; Vega, Jose Velazquez et al. (2018) Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. NPJ Precis Oncol 2:24
Ferris, Matthew J; Liu, Yuan; Ao, Jingning et al. (2018) The addition of chemotherapy in the definitive management of high risk prostate cancer. Urol Oncol 36:475-487
Halicek, Martin; Little, James V; Wang, Xu et al. (2018) Deformable Registration of Histological Cancer Margins to Gross Hyperspectral Images using Demons. Proc SPIE Int Soc Opt Eng 10581:
Cassidy, Richard J; Switchenko, Jeffrey M; El-Deiry, Mark W et al. (2018) Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas. Laryngoscope :

Showing the most recent 10 out of 331 publications